U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H12F5N5O2
Molecular Weight 401.2908
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of STX-478

SMILES

CC1=C(OC2=C1C=C(F)C=C2F)[C@@H](NC(=O)NC3=CN=C(N)N=C3)C(F)(F)F

InChI

InChIKey=LGPNQALKGDDVBD-CYBMUJFWSA-N
InChI=1S/C16H12F5N5O2/c1-6-9-2-7(17)3-10(18)12(9)28-11(6)13(16(19,20)21)26-15(27)25-8-4-23-14(22)24-5-8/h2-5,13H,1H3,(H2,22,23,24)(H2,25,26,27)/t13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H12F5N5O2
Molecular Weight 401.2908
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 19:19:24 GMT 2023
Edited
by admin
on Sat Dec 16 19:19:24 GMT 2023
Record UNII
AGX9NKC8M9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
STX-478
Code English
N-(2-Amino-5-pyrimidinyl)-N′-[(1R)-1-(5,7-difluoro-3-methyl-2-benzofuranyl)-2,2,2-trifluoroethyl]urea
Systematic Name English
Urea, N-(2-amino-5-pyrimidinyl)-N′-[(1R)-1-(5,7-difluoro-3-methyl-2-benzofuranyl)-2,2,2-trifluoroethyl]-
Systematic Name English
Code System Code Type Description
FDA UNII
AGX9NKC8M9
Created by admin on Sat Dec 16 19:19:24 GMT 2023 , Edited by admin on Sat Dec 16 19:19:24 GMT 2023
PRIMARY
PUBCHEM
166532451
Created by admin on Sat Dec 16 19:19:24 GMT 2023 , Edited by admin on Sat Dec 16 19:19:24 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
STX-478 is a second-generation, allosteric, mutant-selective, PI3Kα small molecule inhibitor
ALLOSTERIC
Related Record Type Details
ACTIVE MOIETY
STX-478 is a second-generation, allosteric, mutant-selective, PI3Kα small molecule inhibitor. It is highly selective for the prevalent H1047X (eg, H1047L and H1047R), M1043I, and G1049R kinase domain mutations that comprise over 40% of all PI3Kα mutations in breast cancers